Differentiation therapy for IDH1/2 mutant malignancies
Recently discovered recurrent somatic mutations in the key metabolic enzymes IDH1 and IDH2 produce the aberrant oncometabolite 2-HG and contribute to malignant transformation of hematopoietlc and glial cells.Two recent reports in Science describe the first IDH1 and IDH2 mutant-specific small-molecule inhibitors,which induce cell differentiation of myeloid leukemias and malignant gliomas.
Somatic mutations in epigenetic modifiers and dysregulation of the epigenetic landscape are fundamental contributors to malignant transformation.Acute Myeloid Leukemia (AML) is the most common acute leukemia affecting adults.
23
2013-10-16(万方平台首次上网日期,不代表论文的发表时间)
共3页
975-977